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Abstract
Cancer remains among the most challenging human diseases. Several lines of
evidence suggest that carcinogenesis is a complex process that is initiated by DNA
damage. Exposure to clastogenic agents such as heavy metals, ionizing radiation
(IR), and chemotherapy drugs may cause chronic mutations in the genomic
material, leading to a phenomenon named genomic instability. Evidence suggests
that genomic instability is responsible for cancer incidence after exposure to
carcinogenic agents, and increases the risk of secondary cancers following
treatment with radiotherapy or chemotherapy. Melatonin as the main product
of the pineal gland is a promising hormone for preventing cancer and improving
cancer treatment. Melatonin can directly neutralize toxic free radicals more
efficiently compared with other classical antioxidants. In addition, melatonin is
able to regulate the reduction/oxidation (redox) system in stress conditions.
Through regulation of mitochondrial nction and inhibition of pro‐oxidant enzymes,
melatonin suppresses chronic oxidative stress. Moreover, melatonin potently
stimulates DNA damage responses that increase the tolerance of normal tissues to
toxic effect of IR and may reduce the risk of genomic instability in patients who
undergo radiotherapy. Through these mechanisms, melatonin attenuates several
side effects of radiotherapy and chemotherapy. Interestingly, melatonin has
shown some synergistic properties with IR and chemotherapy, which is distinct
from classical antioxidants that are mainly used for the alleviation of adverse
events of radiotherapy and chemotherapy. In this review, we describe the
anticarcinogenic effects of melatonin and also its possible application in clinical
oncology.
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1 | INTRODUCTION
Cancer is one of the most challenging diseases and is responsible for
a considerable proportion of death in the world. It has been reported
that in 2012 more than 14 million new cases of cancer were
identified, and more than 8 million of whom died (Ferlay et al., 2015).
Nowadays, it is well known that damage to DNA and genomic
instability are among the main factors involved in the initiation of
carcinogenesis. Genomic instability is associated with abnormal DNA
mutations, which can be transferred to the next generation of the
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cells. It is confirmed that various types of cytotoxic agents such as
nonionizing radiation, heavy metals, and also anticancer drugs,
including ionizing radiation (IR) and chemotherapy drugs, are able
to impair the genomic content of cells (Najafi, Cheki, et al., 2018).
Exposure to these agents increases the risk of carcinogenesis and
elevates the risk of second primary malignancies following radio-
therapy or chemotherapy in patients with cancer (Burt, Ying, Poppe,
Suneja, & Gaffney, 2017; Hamilton, Tyldesley, W. Li, Olson, &
McBride, 2015).
Melatonin is considered as a neural hormone, which regulates the
circadian rhythm and sleep cycles. This agent can also be obtained
from some herbal agents such as some fruits and vegetables, grains,
nuts, and seeds (Meng et al., 2017). Nowadays, melatonin is
prescribed as a sleeping aid, while a large body of data have reported
various useful effects (Blask, 2009). One of the most interesting
properties of melatonin is the potent antioxidant activity that can
prevent aging and several diseases such as cancer and neurodegen-
erative diseases (Anisimov, 2003; R. J. Reiter, 1995, 2004; R. Reiter,
Tan, & Allegra, 2002; D. Tan et al., 2002). Through the N1‐acetyl‐N2‐
formyl‐5‐methoxykynuramine (AFMK) pathway, melatonin is able to
neutralize different types of free radicals (S. Cho, Joh, Baik, Dibinis, &
Volpe, 1997). In addition to its direct action, melatonin is able to
neutralize free radicals via stimulation of antioxidant enzymes or
suppression of redox enzymes activity (Pablos et al., 1995; R. Reiter
et al., 1999). These properties may make it a potential agent for
radioprotection during radiotherapy or exposure to nuclear or
radiological pollutants or warfare (Najafi, Shiraz, Motevaseli,
Rezaeyan et al., 2017; Yahyapour et al., 2017, 2018).
It has been shown that there is a direct association between
decreased serum levels of melatonin and increased oxidative DNA
damage. Animal models have revealed that administration of
melatonin reduces the risk of tumorigenesis and prevents the
proliferation of cancer cells (Blask et al., 1999; Dauchy et al.,
2009). Moreover, some epidemiological evidence suggests that low
levels of melatonin are associated with increased risk of some
malignancies such as breast and prostate cancers (Schernhammer &
Schulmeister, 2004; Stevens, 2005; Tai, Huang, Bao, & Wu, 2016). In
addition to its preventive role, recent studies have suggested that
melatonin can be used as an adjuvant for increasing therapeutic
outcome and reducing side effects of radiotherapy and chemother-
apy (Najafi, Shiraz, Motevaseli, Geraily et al., 2017).
2 | MELATONIN: BASIC BIOLOGY
In most species including human, the pinealocytes in the pineal gland
are the primary source for melatonin biosynthesis. However, some
other tissues and cells such as gastrointestinal tract, retina, harderian
gland, iris ciliary body, lacrimal gland, and also leukocytes have been
reported to be involved in melatonin production. In the process of
melatonin biosynthesis, tryptophan amino acids are converted to
serotonin. Then, the enzyme arylalkylamine‐N‐acetyltransferase
converts serotonin to N‐acetylserotonin, which is subsequently
metabolized to the melatonin (Klein et al., 1997; Zheng, Scheibner,
Ho, & Cole, 2001). The biosynthetic pathway of melatonin production
has been reported in details in several studies. In the first step,
tryptophan is uptaken from the circulation and converted into
5‐hydroxytryptophan by the tryptophan hydroxylase. The activity of
this enzyme increases during darkness by about two folds. Then
5‐hydroxytryptophan is converted to serotonin and then melatonin
by arylalkylamine‐N‐acetyltransferase in the pineal gland. The
activity of N‐acetyltransferase is highly dependent on the circadian
rhythm, being increased by around 100 folds at night.
In mammalians, melatonin is able to affect cellular functions
through interaction with some receptors. Two different G protein‐
coupled melatonin receptors, including metallothionein 1 (MT1) and
MT2, have been identified. Melatonin is also able to attenuate
transfer of electrons to quinones through binding to MT3, leading to
the amelioration of oxidative stress. Furthermore, melatonin has
been proposed as a stimulator of the retinoid orphan nuclear
receptor α (RORα; Wiesenberg, Missbach, Kahlen, Schräder, &
Carlberg, 1995). RORα has a high expression in some malignancies
such as lymphoma, leukemia, brain, breast, and central nervous
system cancers (Du & Xu, 2012). Melatonin induces apoptosis and
growth inhibition in some cancer cells such as colon and pituitary
cancers through modulation of RORα (Karasek, Gruszka, Lawnicka,
Kunert‐Radek, & Pawlikowski, 2003; Winczyk, Pawlikowski,
Guerrero, & Karasek, 2002). Through stimulation of its receptors
including MT1, MT2, and RORα, melatonin has been shown to affect
immune cells activity, thereby stimulates antitumor activity of
immune cells (Pozo, Garcia‐Maurino, Guerrero, & Calvo, 2004).
3 | MELATONIN PREVENTS GENOMIC
INSTABILITY AND CANCER INCIDENCE
3.1 | Neutralization of free radicals
Free radicals are one of the main toxic product of interaction of
exogenous agents within cells. Although, free radicals are
normally produced by some interactions and are involved in
various signaling pathways within cells, abnormal increase of
their production can hurt vital organelles in cells (Bókkon, 2012).
Oxygen free radicals are the most destructive type of oxygen
metabolites. Reactive oxygen species (ROS) can be found as some
types including high‐reactive hydroxyl radical (OH), and also low‐
reactive superoxide anion radical (O2
−) and hydrogen peroxide
(H2O2). High‐reactive free radicals can attack to DNA, lipids, and
proteins that are in the vicinity of free radical’s origin (Lobo, Patil,
Phatak, & Chandra, 2010). As these free radicals are highly
reactive, it can interact with vital molecules within some
nanosecond. Although H2O2 is low reactive compared with other
type of ROS, it can be generated to H2O and high toxic O2
−.
On the other hand, O2
− interacts with nitric oxide (NO), leading
to the production of the peroxynitrite anion (ONOO−).
Peroxynitrite and NO are named reactive nitrogen species (Tacar,
Sriamornsak, & Dass, 2013). These two type of free radicals are
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highly reactive, which are able to damage to adjacent cells
(R. J. Reiter, Manchester, & Tan, 2010).
The potent free‐radical scavenging effects of melatonin has been
found by some experimental studies (Marshall, Reiter, Poeggeler,
Aruoma, & Halliwell, 1996; Poeggeler et al., 1994). After that it has
shown that melatonin neutralizes free radical by donate of electron.
Their experiments showed that melatonin scavenges OH more
efficiently compared with other antioxidants including glutathione or
mannitol (Poeggeler, Reiter, Hardeland, Tan, & Barlow‐Walden, 1996).
After that it has confirmed that melatonin is able to neutralize other
types of free radicals such as H2O2, NO, ONOO
−, and also singlet
oxygen and O2
− (D. X. Tan et al., 2002; D. Tan et al., 2000). In addition to
melatonin itself, other its metabolites such as cyclic 3‐hydroxymelatonin
N1‐acetyl‐5‐methoxykynuramine (AMK), 6‐hydroxymelatonin, 2‐hydro-
xylmelatonin, 6‐hydroxylmelatonin, and AFMK have potent ROS
scavenger (Álvarez‐Diduk, Galano, Tan, & Reiter, 2015; Galano, Tan, &
Reiter, 2013; R. J. Reiter et al., 2016). In response to IR, a large body of
studies have revealed the antioxidant effect of melatonin. Besides direct
actions on free radical scavenging, melatonin stimulates ROS/NO
scavenging enzymes potently, thus more metabolize ROS and NO,
and further protect against oxidative stress. Treatment of rats with
10mg/kg melatonin before exposure to different doses of IR can
potently alleviate oxidative stress markers and augments antioxidant
enzymes like reduced glutathione (GSH), glutathione‐S‐transferase, and
catalase in liver (El‐Missiry, Fayed, El‐Sawy, & El‐Sayed, 2007). Similar
results have obtained in rat lens after injection of 5mg·kg−1·day−1
melatonin (Shirazi et al., 2011; Taysi et al., 2008). Reduce of oxidative
stress, DNA damage, and lipid peroxidation by melatonin have shown by
other in vivo studies (Bhatia & Manda, 2004; Guney et al., 2007; Take
et al., 2009).
3.2 | Suppression of reduction/oxidation (redox)
system
In addition to direct free radical production by toxic agents, such as
IR or chemotherapy drugs, redox interactions have key roles in cell
toxicity. The main sources of ROS and NO production within cells are
mitochondria, membrane, lipoxygenases (LOXs), cyclooxygenases
(COXs), nicotinamide adenine dinucleotide phosphate hydrogenase
(NADPH) oxidases, inducible nitric oxide synthase (iNOS), and some
others. Several experiments have reported that chronic upregulation
of redox enzymes is associated with increased risk of carcinogenesis
(Najafi, Motevaseli, et al., 2018).
3.3 | Mitochondrial preservation
Mitochondria are vital organelles within cells, because their roles in
oxidative phosphorylation and energy supply. During oxidative
phosphorylation, the produced electrons in electron transport chain
(ETC) are captured by the cytochrome c and coenzyme Q and then
transported to oxygen molecules. This process leads to the
production of water, while it is possible some electrons cause
reduction of oxygen molecules to form O2
− (D.‐X. Tan, Manchester,
Qin, & Reiter, 2016). Damage to mitochondrial DNA (mtDNA) is
associated with increased production of superoxide, leading to
chronic oxidative stress. Released ROS from mitochondria can
stimulate other inflammatory mediators, such as macrophages to
further product ROS and NO, leading to more oxidative injury via a
phenomenon named ROS‐induced ROS (Zorov, Juhaszova, & Sollott,
2006). Damage to mitochondria and stimulation of ROS production
following exposure to IR has confirmed in several experiments. van
Gisbergen et al. (2017) in an in vitro study showed that when A549
or 143B cell lines irradiated, the level of ROS and DNA double‐strand
breaks increase. However, after depletion of A549 or 143B cells from
mitochondria the ROS production was decreased (van Gisbergen
et al., 2017). Results of this study are parallel with another study by
Yoshida et al. (2000) that showed the presence of mtDNA can
augment micronucleus formation after irradiation. This is associated
with the reduction of cell survival (Yoshioka et al., 2004). In addition
to mutation in mtDNA, it is proposed that mitochondria malfunction
is associated with loss of calcium homeostasis, which leads to
enhanced free radicals production and cell death (Frandsen &
Schousboe, 1993).
Studies have revealed that melatonin regulates mitochondrial
homeostasis (Castroviejo et al., 2002). It has been proposed that
melatonin neutralizes both ROS and NO in the mitochondria, which
lead to improved oxidative phosphorylation (Castroviejo et al., 2002;
Leon, Acuna‐Castroviejo, Escames, Tan, & Reiter, 2005; M. Martín
et al., 2002). An experiment by M. Martín, Macías, Escames, León, and
Acuña‐Castroviejo (2000) showed that the melatonin, but no other
antioxidants such as ascorbic acid or gamma‐tocopherol, regulates
redox status oxidative stress condition. Inflammasome and inflam-
matory mediators are other targets of melatonin. The inflammasome
is a complex containing some proteins that regulate the release of
interleukin‐1β (IL‐1β) and IL‐18, and also activation of some
proapoptotic pathways (Guo, Callaway, & Ting, 2015). Melatonin is
able to inhibit inflammasome after damage to mitochondria, leading
to the attenuation of inflammatory cytokines and mucositis following
irradiation of gastrointestinal system. As inflammatory responses and
mitochondrial disruption following exposure to radiation are involved
in chronic oxidative stress, melatonin ameliorates DNA damage via
this pathway (Fernández‐Gil et al., 2017; Ortiz et al., 2015).
In addition to energy supply to activities of the cells, the
mitochondria play a key role in apoptosis signaling pathway. On
the other hand, high incidence of apoptosis in some organs such as
bone marrow and gastrointestinal system make them sensitive to IR
or chemotherapy (Gudkov & Komarova, 2003; Tacar et al., 2013).
High radiosensitivity of these organs limit received radiation dose to
tumors within or adjacent to them. So, inhibition of apoptosis and
free radical’s production by mitochondria have suggested for
mitigation of radiation injury in these organs (Yahyapour et al.,
2018). Upregulation of Bcl‐2‐associated X protein (Bax) and caspase
genes play a key role in this process. Increased level of Bax protein
cause release of cytochrome c from ETC, leading to the production of
apoptosome complex (Marsden et al., 2002). A study by Tang et al.
(1999) showed that mtDNA is involved in apoptosis induction and
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radiation sensitivity following exposure to IR. They showed that
when cells depleted from mtDNA (RHO cells), the sensitivity to IR is
reduced. It has reported that melatonin can prevent the apoptosis
cascade during stress conditions. The ROS scavenging ability of
melatonin prevents damage to mtDNA and the ETC proteins in
oxidative stress situations, which cause stability of mitochondria
function (Acuna‐Castroviejo et al., 2001; Garciá et al., 1999).
Melatonin also, can regulate the apoptosis through modulation of
mitochondrial proapoptosis genes. Pretreatment of rats with 10 or
100mg/kg melatonin cause significant reduction of Bax and increase
of B‐cell lymphoma 2 (Bcl‐2) gene expression, as well as incidence of
apoptosis after exposure to IR (Mohseni et al., 2012).
3.4 | Other pro‐oxidant enzymes
As mentioned above, in addition to mitochondria some other
enzymes are involved in ROS and NO production following exposure
to IR and chemotherapy. Cyclooxygenase‐2 (COX‐2) is a central
isoenzyme in the inflammation, which is associated with increased
risk of cancer incidence (J. R. Brown & DuBois, 2005; Harris,
Beebe‐Donk, & Alshafie, 2006; D. Wang & DuBois, 2010). COX‐2
upregulation is associated with ROS production during prostaglandin
production. Moreover, COX‐2 can increase the release of proin-
flammatory cytokines and amplification of redox activity (D. Wang &
DuBois, 2010). In response to IR, it has been shown that COX‐2 is
involved in oxidative DNA damage and genomic instability (Mohsen
Cheki et al., 2018). Suppression of this enzyme by its inhibitors has
been shown to alleviate radiation toxicity in the bone marrow and
joints (El‐Ghazaly, Nada, El‐Hazek, & Khayyal, 2010; Hosseinimehr,
Fathi, Ghasemi, Shiadeh, & Pourfallah, 2017). This is associated with
the reduction of inflammatory cytokines such as IL‐1 and tumor
necrosis factor α (Khayyal, El‐Ghazaly, El‐Hazek, & Nada, 2009).
Melatonin can regulate COX‐2 expression and enzyme activity. In
addition, it has been revealed that in response to IR the melatonin via
inhibition of COX‐2 prevents the upregulation of iNOS, thus more
attenuate oxidative injury and inflammatory responses (Fardid
et al., 2017).
NADPH oxidase (NOX) including NOX1–5 and dual oxidase
1 (DUOX1) and DUOX2 are H2O2 producing enzymes, which are
activated in response to several cytokines and growth factors. It has
been shown that upregulation of these enzymes is associated with
genomic instability, and also the development of collagen and fibrosis
(Chang et al., 2015; Choi et al., 2016; Sakai et al., 2018; Sato et al.,
2016; Y. Wang, Liu, et al., 2010). D. Li et al. (2016) in an in vivo study
evaluated the potential radioprotective effect of melatonin through
NOX4 expression in mice bone marrow. They revealed that
treatment with melatonin or 5‐methoxytryptamine‐α‐lipoic acid
(a combination of melatonin with α‐lipoic acid) significantly attenu-
ates NOX4‐derived ROS, DNA damage, and apoptosis in hemato-
poietic stem cells (D. Li et al., 2016).
LOXs are another type of pro‐oxidant enzymes that have
proposed for radiation‐induced redox activity (Yahyapour et al.,
2018). These enzymes catalyze the insertion of oxygen molecules
into polyunsaturated fatty acids, which mediate the synthesis of
inflammatory leukotrienes from arachidonic acid (K.‐J. Cho, Seo, &
Kim, 2011). This is associated with ROS production and oxidative
DNA damage (Blair, 2001; Jian, Lee, Williams, & Blair, 2009; Speed &
Blair, 2011). It has shown that the pineal hormone melatonin
regulates the expression of LOXs gene (Radogna, Diederich, &
Ghibelli, 2010; Uz, Longone, & Manev, 1997). It is proposed that
melatonin via binding to a nuclear receptor RZR/RORα (a stimulator
of LOX gene) inhibits expression and production of LOXs (Steinhilber
et al., 1995).
3.5 | Stimulation of DNA repair responses
DNA damage is the first consequence of exposure of cells to IR and
chemotherapy agents such as cyclophosphamide and doxorubicin
(Cohen & Lippard, 2001). Damage to DNA and cell death leads to the
release of alarmins for immune system cells including macrophages,
dendritic cells, and lymphocyte T (Bianchi, 2007; Yang, de la Rosa,
Tewary, & Oppenheim, 2009). In response to danger alarms, these
immune cells release several types of cytokines that more stimulate
ROS and NO production by redox mediators (Krysko et al., 2011). So,
enhance of DNA repair responses can reduce cell death and also
attenuate inflammation and redox activity. In addition, some studies
have revealed that inflammation is a potent inhibitor of DNA damage
response (Najafi, Cheki et al., 2018). NO, which is released by iNOS
following activation of macrophages and lymphocyte T, is capable to
suppress DNA damage response (Moritz et al., 2014). The main
target for NO is 8‐oxoguanine glycosylase 1 (Ogg1), a DNA repair
enzyme in base excision repair (BER) pathway. NO cause nitroace-
tylation and inactivation of Ogg1, leading to attenuation of other
downstream genes, including apurinic/apyrimidinic endodeoxyribo-
nuclease 1 (Apex1), and X‐ray repair cross complementing 1 (Xrcc1).
Through this pathway, NO can promote accumulation of DNA
damage and promotion of genomic instability (Najafi, Cheki,
et al., 2018).
Melatonin has shown that accelerates kinetic of DNA repair
following exposure of DNA to ROS. A study showed that when
human lymphocytes are exposed to H2O2, cells require 120min to
complete the repair process, while treatment with melatonin reduces
this time to 10min (Sliwinski et al., 2007). A study by Santoro, Marani,
Blandino, Muti, and Strano (2012) proposed that melatonin through
activation of p53 reduces accumulation of DNA damage and risk of
genomic instability. They revealed that melatonin is able to
phosphorylate p53 without need to ataxia telangiectasia‐mutated
expression. More analyses showed that phosphorylation of p53
melatonin is depended to p38 mitogen‐activated protein kinase
(MAPK) and promyelocytic leukemia protein gene upregulation. This
study showed that treatment of human breast cells with melatonin
reduces changes in genomic content following exposure to DNA
damage agents such as cisplatin, antimetabolite fluorouracil (FU),
topoisomerase inhibitor, or IR. These results are indicated potent
inhibitory effect of melatonin on genomic instability and carcinogen-
esis (Santoro et al., 2012).
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Rezapoor et al. (2017) evaluated the effect of pretreatment
with melatonin on radiation‐induced BER pathway genes. They
administrated 100 mg/kg to rats at 30 min before irradiation with
2 or 8 Gy X‐rays. Then, circulating lymphocytes extracted at 8,
24, and 48 hr after irradiation and the expression of BER pathway
genes including Ogg1, Apex1, and Xrcc1 were detected. Results
indicated that melatonin alone increase three genes potently
when they compared with nontreated group. Although, exposure
to IR caused potent inhibition of all genes in mentioned times,
treatment with melatonin reverse regulation of those. The
stimulatory effect of melatonin was clearer for 2 Gy irradiated
rats, indicating it needs to more dose of melatonin for stimulation
of DNA damage response for against higher doses of IR
(Rezapoor et al., 2017). By similar method, another study showed
that melatonin treatment augments the regulation of Xrcc4 and
Ku70 in rat’s lymphocytes. This was more obvious at 24 hr after
exposure to IR (Valizadeh et al., 2016; Valizadeh, Shirazi, Izadi,
Tavakkoly Bazzaz, & Rezaeejam, 2017). Moreover, melatonin
treatment before irradiation has shown is able to regulate genes
involved in nonhomologous end joining (NHEJ) pathway, includ-
ing RAD50 and Cdkn1 (Rezaeejam et al., 2018).
In addition to IR, melatonin has shown to enhance DNA damage
responses against chemotherapy agents. Bennukul, Numkliang, and
Leardkamolkarn (2014) evaluated the effect of melatonin on
cytotoxicity of cisplatin on hepatocellular carcinoma (HepG2) cells.
This study showed that treatment of this cell type with 1mmol/L
melatonin lead to a reduction in DNA damage and apoptosis,
as well as an increase in ERCC1 gene, which is involved in
nucleotide excision repair (NER) pathway of DNA damage repair
(Bennukul et al., 2014).
3.6 | Antiestrogenic effect of melatonin
Based on various evidence it is confirmed that estrogen has a key
role in stimulating the proliferation of the neoplastic breast
epithelium (Bouris et al., 2015; B. Huang, Warner, & Gustafsson,
2015; Santen, Yue, & Wang, 2015). Moreover, expression of estrogen
receptors increases as the cancer progresses (B. Huang et al., 2015;
Soysal et al., 2015). Estrogen through regulation of cell proliferation
and apoptosis may trigger neoplasm (Andruska, Zheng, Yang,
Helferich, & Shapiro, 2015). It seems that stimulation of MAPKs
including extracellular signal‐regulated kinase (ERK) and p38 genes,
and also Akt1 and signal transducer and activator of transcription
5 (Stat5) play a key role in this pathway (Mao et al., 2010; Xiang et al.,
2012; Zivadinovic & Watson, 2005). Experimental studies have
revealed that there is a direct relation between estrogen receptors
and breast cancer cell proliferation (Zivadinovic, Gametchu, &
Watson, 2005). Epidemiologic studies have confirmed a direct
relation between serum estrogen level and risk of breast cancer
(S. B. Brown & Hankinson, 2015). Melatonin has shown suppress
breast cancer proliferation by affecting estrogen receptors.
Kiefer, Ram, Yuan, and Hill (2002) showed that treatment of
F IGURE 1 Mechanisms of protective effect of melatonin against DNA damage and genomic instability. Melatonin is able to prevent inflammation
and redox activity in different levels. Also, it prevents genomic instability via neutralization of nitric oxide and stimulation of BER pathway genes.
CAT: catalase; COX: cyclooxygenase; IFN: interferon; IL: interleukin; iNOS: inducible nitric oxide synthase; MAPK: mitogen‐activated protein kinase;
NO: nitric oxide; Ogg1: 8‐oxoguanine glycosylase 1; ROS: reactive oxygen species; TGF‐β: transforming growth factor β; TNF‐α: tumor necrosis factor α;
STAT5: signal transducer and activator of transcription 5 [Color figure can be viewed at wileyonlinelibrary.com]
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MCF‐7 cells with melatonin suppresses growth of breast cancer cells
with estrogen receptor‐positive cells (Kiefer et al., 2002). Another
study by Lopes, Arnosti, Trosko, Tai, and Zuccari (2016) has shown
that melatonin treatment of human breast cancer stem cells inhibit
proliferation via downregulation of estrogen receptor α and the
transcription factor OCT4 (Lopes et al., 2016; Figure 1).
4 | TUMOR SUPPRESSIVE EFFECTS OF
MELATONIN
In addition to preventative effects of melatonin on cancer incidence,
a large body of studies have reported that it is able to suppress tumor
growth, proliferation, and metastasis. Studies propose various
mechanisms for tumor inhibiting effect of melatonin such as
induction of apoptosis, stimulation of immune system cells, inhibiting
repopulation and angiogenesis genes, and others. Also, studies have
revealed that administration of melatonin associated with che-
motherapy or radiotherapy may increase therapeutic effect of these
modalities.
4.1 | Induction of apoptosis
One of the interesting properties of melatonin is clastogenic effect
on tumor cells. This is in contrast by other results that indicated
potent protective effect of melatonin on normal cells. Moreover, by
contrast to normal cells, some studies propose that melatonin can
induce apoptosis in cancer cells. In a study by K. J. Kim et al. (2013)
has shown that melatonin treatment of human prostate cancer cells
potently stimulates apoptosis in a dose‐dependent manner. They
showed that treatment of cells with 3mM melatonin can reduce
viability of cells up to 80% in 48 hr after treatment. Western blot
analysis results showed a significant increase in protein level of Bax,
caspase‐3, and caspase‐9, as well as a potent reduction in Bcl‐2.
Authors showed that activation of p53 by melatonin play a key role in
initiation of apoptosis signaling pathway (C. H. Kim & Yoo, 2010).
Another study showed that melatonin via activation of MAPKs
pathway induce apoptosis in prostate cancer cells (Joo & Yoo, 2009).
Moreover, it has proposed that melatonin via inhibition of nuclear
factor‐κB (NF‐κB; an antiapoptosis gene) facilitate apoptosis induc-
tion in cancer cells (W. Li et al., 2015).
Gatti et al., (2017) evaluated apoptosis induction effect of
melatonin on human melanoma and breast cancer cell lines. They
used from four analogs of melatonin at different concentrations.
Results showed that a concentration of 10−4 M has a significant
effect on apoptosis induction in breast cancer cell lines including
MCF‐7, DX3, UCM 1037, and MDA‐MB231 cells. Melatonin
treatment showed is able to suppress Bcl‐2 expression in melanoma
WM‐115 cell line, while it shows has no effect on Bax/Bcl‐2 ratio in
other cell types. In other hand, melatonin increase regulation of
caspase‐3 in DX3 cells, while it did not increase in melanoma cells.
These results may indicate that melatonin activate apoptosis via
different pathways in different types of cancer cells (Gatti et al.,
2017). Activation of caspase‐3 and apoptosis in human neuroblasto-
ma cancer cells have reported (Garcia‐Santos et al., 2006). Similar
results have reported in other studies (Chovancova et al., 2017;
Chuffa et al., 2016; Fan et al., 2013; Sainz et al., 2003; Zha et al.,
2012). By contrast to these studies, in a study have shown that
treatment of human breast cancer cells and colorectal carcinoma
cells with melatonin do not cause increase in apoptosis induction.
Authors proposed that possibly there is a high dose of melatonin for
apoptosis induction (Santoro et al., 2012). It seems that induction of
apoptosis is dependent on melatonin concentration. Some studies
have proposed that, while cytotoxic effects of melatonin may appear
in nanomolar concentrations, induction of apoptosis requires higher
concentrations, for example at millimolar concentrations (Bizzarri,
Proietti, Cucina, & Reiter, 2013; Talib, 2018). In addition to that,
Cucina et al. (2009) showed that apoptosis induction in MCF‐7 cells
following melatonin treatment has a biphasic pathway. They showed
that apoptosis can be induced through different pathways at
different times following melatonin treatment. Results showed that
early peak of apoptosis can be observed at 24 hr after treatment
because of caspase activation, while late peak is seen at 96 hr after
treatment that is caspase independent (Cucina et al., 2009).
4.2 | Suppression of tumor cells repopulation
It has been confirmed that after apoptosis in tumor cells, increased
caspase‐3 lead to stimulation of prostaglandins production, which
mediate proliferation of tumor cells (Galluzzi, Kepp, & Kroemer,
2012; Q. Huang et al., 2011). Through this pathway, activation of
caspase‐3 and elevated level of COX‐2 and subsequent prostaglan-
dins promote regrowth and resistance of tumor cells (Donato et al.,
2014; Galluzzi et al., 2012). It has shown that prostaglandin E2,
which is a product of COX‐2, is involved in tumor resistance and
repopulation during radiotherapy (Q. Huang et al., 2011). Melatonin
as a COX‐2 inhibitor has shown attenuate production of prosta-
glandins and tumor cell repopulation (Woo, Min, & Kwon, 2015).
Panzer and Viljoen (1997) found that melatonin can act as an
anticancer agent in breast cancer through a decrease in cell
proliferation and suppression of some antiapoptotic mediators
including NF‐κB and COX‐2. Antiproliferative effect of melatonin
has been shown for prostate cancer cells too (Sainz et al., 2005; Siu,
Lau, Tam, & Shiu, 2002). In recent years has shown that melatonin
via downregulating the cyclin‐dependent kinases, including CDK2
and CDK4 suppress proliferation of ovarian cancer cells (Shen,
Chang, Chen, Lai, & Hsu, 2016). Similar results obtained for
osteosarcoma cells (L. Liu, Xu, & Reiter, 2013). In a study by
Santoro et al. (2012) have revealed that treatment of MCF‐7 cells
with melatonin attenuate proliferation and colony formation of this
cell. Further analyses showed a transient arrest in G2 phase of cell
cycle. In the breast, ovarian, osteosarcoma, and colon endometrial
cancer cells have been shown that melatonin inhibit proliferation
through melatonin receptors including the MT1 and MT2 (Jablonska
et al., 2013, 2014; León et al., 2012; Treeck, Haldar, & Ortmann,
2006; Watanabe, Kobayashi, Takahashi, Kiguchi, & Ishizuka, 2008).
6 | FARHOOD ET AL.
4.3 | Melatonin and immune cells
A large number of studies have revealed a potent association
between melatonin and the immune system (Labrecque & Cermakian,
2015; Ozkanlar et al., 2016; Vinther & Claësson, 2015). It well known
that melatonin is produced not only by the pineal gland, but also it
can be released by the retina, kidneys, digestive tract, and also by
peripheral blood mononuclear cells (Emet et al., 2016; Tordjman
et al., 2017). This may suggest a potent interrelation between the
immune system and melatonin in different organs (Ren et al., 2017).
Some studies proposed that melatonin through its receptors on
immune cells influences proliferation of immune cells and release of
cytokines (Carpentieri, Peralta lopez, Aguilar, & Solá, 2017; Singh &
Jadhav, 2014). Furthermore, melatonin has shown that is able to
stimulate natural killer cell activity in humans, as increase antitumor
activity of immune system (Miller, Pandi, Esquifino, Cardinali, &
Maestroni, 2006). Another immune system cell, which has a key role
in tumor response to therapeutic modalities is regulatory T cells
(Tregs). In normal conditions, these cells attenuate immune system
effects and suppress autoimmune reactions. But, in tumor cells,
infiltration of these cells cause resistance of tumor cells via reduction
of cytotoxic cells activity (Vinay et al., 2015). H. Liu et al. (2011)
showed that melatonin is able to induce gastric cancer cell death in
mice bearing tumor via suppression of Tregs. Melatonin was effective
when it administrated in 100mg/kg but not for 25 or 50mg/kg.
5 | MELATONIN EFFECTS ON
ANGIOGENESIS
Angiogenesis is a key procedure that is necessary for tumor growth
and metastasis. Thus, angiogenesis is an interesting target for tumor
control and treatment (Potente, Gerhardt, & Carmeliet, 2011;
Trachsel & Neri, 2006). The vascular endothelial growth factor
(VEGF) is a key mediator for development of new vessels and
promotion of angiogenesis in both normal and malignant cells. VEGF
has three important receptors, including VEGF‐1, VEGF‐2, and
VEGF‐3, while its main effect is mediated through VEGF‐1 (Hicklin
& Ellis, 2005; Pradeep, Sunila, & Kuttan, 2005; Shinkaruk, Bayle, Lain,
& Deleris, 2003; Sousa Moreira, Alexandrino Fernandes, & Joao
Ramos, 2007). Targeting of VEGF‐1 for inhibiting tumor angiogenesis
and growth have proposed by several studies (Underiner, Ruggeri, &
Gingrich, 2004; Veeravagu et al., 2007). However, some studies
proposed targeting of VEGF‐2 or VEGF‐3 (Shi, Wu, & Li, 2015;
Tammela et al., 2008). However, clinical studies have shown that
selective inhibition of this receptor with selective inhibitors such as
bevacizumab is associated with severe side effects such as skin rash
and disruption of wound healing (Bodnar, 2014; Ishak, Aad, Kyei, &
Farhat, 2014; Macdonald, Macdonald, Golitz, LoRusso, & Sekulic,
2015; Wozel, Sticherling, & Schön, 2010).
Melatonin has shown interesting properties in tumor growth
by suppression of angiogenesis markers. In a study including 20
metastatic patients the effect of melatonin treatment has detected
on serum level of VEGF. The patients used melatonin as 20 mg/day
for 2 months and the level of VEGF were detected. Results showed
a significant reduction of median level VEGF in the serum
of patients (Lissoni et al., 2001). An in vitro study by
Carbajo‐Pescador et al. (2013) showed that melatonin attenuates
the expression of VEGF in HepG2 cells through modulation of
hypoxia‐inducible factor 1 (HIF‐1) and STAT3. Their results
proposed that melatonin in a pharmacological concentration
(1 mM) is able to inhibit VEGF stimulation during hypoxia situation
(Carbajo‐Pescador et al., 2013). Jardim‐Perassi et al. (2014)
showed that melatonin treatment of mice bearing human breast
cancer cells cause inhibition of angiogenesis in this tumor by
attenuation of VEGF receptor 2 (VEGFR2) gene expression.
Suppression of VEGFR2 was confirmed by SPECT imaging of
Tc‐99m‐HYNIC‐VEGF‐c and also immunohistochemistry analysis.
Melatonin could not reduce other proangiogenesis factors in this
study (Jardim‐Perassi et al., 2014). However, another study
proposed that melatonin may via downregulation of EGFR and
insulin‐like growth factor 1 reduces angiogenesis in breast cancer
cells (Zuccari et al., 2015). As VEGFR2 is stimulated by HIF‐1
during hypoxia situation, it seems that melatonin is an inhibitor of
breast cancer angiogenesis by downregulation of HIF‐1 (Goradel
et al., 2017; Victorasso jardim‐Perassi et al., 2016). Similar results
were defined for Dalton lymphoma, renal adenocarcinoma, colon
cancer cells, and ovarian carcinoma cells (K. J. Kim et al., 2013;
Kumari, Rawat, Kumari, & Shrivastava, 2017; Park et al., 2010;
Zonta et al., 2017). In the human gastric cancer cells it has been
shown that melatonin beside to VEGF and HIF‐1 can reduce
angiogenesis by suppression of nuclear receptor RZR/RORγ
(R.‐X. Wang, Liu, Xu, Zhang, & Zhou, 2016). It seems that melatonin
through inhibition of RZR/RORγ and sphingosine kinase 1 (SPHK1)
suppresses HIF‐1 and downstream angiogenesis signaling in
gastric cancer (S. Y. Cho, Lee, et al., 2011; R. X. Wang, Liu, Xu,
Zhang, & Zhou, 2015). By contrast to tumor cells, melatonin has
shown to stimulate angiogenesis and wound healing in normal cells
or tissues after injury (Soybir et al., 2003).
6 | SYNERGISTIC EFFECTS OF
MELATONIN IN ONCOLOGY
6.1 | Modulation of cancer response to
radiotherapy with melatonin
An appropriated adjuvant in radiotherapy should have a good
synergistic effect on tumor response to radiation, as well as low
toxicity for normal tissues. Melatonin is known as a radioprotector
more than a radiosensitizer agent. The potent radioprotection of
melatonin on normal tissues have described by several studies. So,
if melatonin is able to sensitize tumor cells to radiotherapy, it may
be used as an ideal adjuvant. Although studies to show radio-
sensitive effect of melatonin on cancer cells are very limited,
some recent studies show interesting results. Alonso‐González,
González, Martínez‐Campa, Gómez‐Arozamena, and Cos (2015) in
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an in vitro study showed that melatonin treatment of MCF‐7 cells
(1 mM, 10 μM, and 1 nM) before irradiation result in a cell cycle
arrest in the G0–G1 phase and reduction of cells in the S phase.
Moreover, melatonin administration before irradiation caused a
downregulation of DNA repair enzymes including RAD51 and
DNA‐PKcs. This may cause accumulation of DNA damage induced
by IR (Alonso‐González et al., 2015). In another study, they
showed that melatonin treatment before irradiation sensitize
MCF‐7 cells to IR via suppression of estrogen biosynthesis, which
leading to inhibition of proliferation. Also, they reported that
melatonin activates p53, a potent initiator of apoptosis in MCF‐7
cells. This effect was more significant in 1 nM compared
with other concentrations of melatonin (1 mM or 10 μM;
Alonso‐González et al., 2016).
A study by Zou et al. (2018) showed that melatonin has a
radiosensitizer effect on thyroid cancer cells too. In in vitro study
their results showed that melatonin inhibits proliferation of
thyroid cancer cells in a dose‐dependent manner. Results showed
a 15% survival when thyroid cancer cells treated with 15 mM for
48 hr. Irradiation of cells lead to an increase in expression of
NF‐κB/p65, an antiapoptosis and cell growth stimulator. While,
when cells treated with melatonin the expression of it inhibited.
Moreover, treatment with melatonin before irradiation lead to
sensitization and reduction of viability of cells when it compared
to irradiation only. Results indicated a dose‐dependent relation
between radiosensitization effect of melatonin and melatonin
concentration. Interestingly, this study showed that melatonin
via stimulation of redox reactions induces ROS production.
Moreover, in in vivo xenograft mouse model, they showed that
melatonin administration in combination with radiation attenu-
ates tumor growth when it compared with irradiation alone (Zou
et al., 2018). Enhancement of radiation toxicity on head and neck
cancer cells have been reported by Escames, Fernández‐Gil, et al.
(2017) they proposed that melatonin through modulation
of mitochondria activity, ROS production, and induction of
apoptosis has a synergistic effect on therapeutic effects of IR
(Escames, Guerra‐Librero et al., 2017).
6.2 | Modulation chemotherapy consequences by
melatonin
In addition to radiotherapy, melatonin also showed some evidence
for potentiating the therapeutic outcome and alleviation of
the chemotherapy side effects (Sanchez‐Barcelo, Mediavilla,
Alonso‐Gonzalez, & Reiter, 2012). Casado‐Zapico et al. (2010)
showed that melatonin can reinforce antitumor effect of vincristine
and ifosfamide on Ewing sarcoma cells. Also, they revealed that the
most effect of melatonin mediate through enhancement of
apoptosis via upregulation of extrinsic apoptosis pathway genes
(Casado‐Zapico et al., 2010). Melatonin has shown that reinforce
effects of chemotherapy drugs such as doxorubicin, cisplatin, and
5‐fluorouracil on HeLa cells. Although, similar to Ewing sarcoma cells
melatonin augments apoptosis, by contrast to this cell the mitochon-
drial apoptosis pathway has main role in synergistic effect of
melatonin. Moreover, melatonin increased ROS production in HeLa
cells, leading to more toxicity of cisplatin (Pariente, Pariente,
Rodríguez, & Espino, 2016). Similar effects were detected for the
rat pancreatic tumor Cells (Uguz et al., 2012). Combinations of
melatonin and temozolomide has a synergistic therapeutic effect on
malignant glioma cells. This is resulting from elevated the methyla-
tion of the ABCG2/BCRP promoter, leading to decreased expression
of this gene. Downregulation of this gene help to more accumulation
of chemotherapy agents in tumor cells, which increase therapeutic
action of chemotherapy (V. Martín et al., 2013).
In clinical trial studies also melatonin showed interesting results
for reducing chemotherapy agent’s toxicity, as well as increasing
therapeutic effect. Administration of 20mg/day orally melatonin
associated with chemotherapy showed that augments 1‐year survival
rate and potentiate regression of tumors (Lissoni et al., 1999).
Administration of same dose of melatonin in combination with
F IGURE 2 Mechanisms of antitumor
activity of melatonin in radiotherapy and
chemotherapy. Melatonin through
suppression of angiogenesis and
proliferation, as well as via stimulation of
apoptosis help to better outcome of
therapy. COX: cyclooxygenase;
MAPK: mitogen‐activated protein kinase;
NF‐κB: nuclear factor‐κB; STAT: signal
transducer and activator of transcription;
VEGF: vascular endothelial growth factor
[Color figure can be viewed at
wileyonlinelibrary.com]
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cisplatin and etoposide to metastatic non‐small‐cell lung cancer
(NSCLC) patients caused a significant tumor regression rate and
increased survival. This study showed that treatment with melatonin
cause 6% survival after 5 years, while no patients were survived
among patients that received chemotherapy without melatonin
(Lissoni, Chilelli, Villa, Cerizza, & Tancini, 2003; Figure 2).
7 | MELATONIN IN ASSOCIATION WITH
TARGETED THERAPIES
Targeted therapy is an effective method for cancer treatment and
involves inhibition of tumor growth receptors, apoptosis resistance
genes such as Bcl‐2, and cellular function (Leverson et al., 2015).
Although inhibition of these targets in cancer cells can effectively
attenuate tumor growth, there is evidence showing that mutations in
these receptors can lead to poor response to prescribed drugs
(Zaretsky et al., 2016). For example, mutations in EGFR in NSCLC
cells causes resistance to EGFR tyrosine kinase inhibitors like
gefitinib and erlotinib (Pao et al., 2005). Combination of melatonin
with some inhibitors have shown better outcomes in suppressing
tumor cells growth compared with using an inhibitor alone. Yun et al.
(2014) evaluated the cytotoxicity of a combination of melatonin with
gefitinib on H1975 cells. Cells that used in this study had a mutation
(T790M) that caused resistance to gefitinib. Results showed that
treatment of H1975 with a combination of melatonin and gefitinib
caused attenuation of EGFR phosphorylation and suppression of
Bcl‐2, culminating in increased apoptosis and reduced cell viability
(Yun et al., 2014).
A study by Prieto‐Domínguez et al. (2017) revealed effective
therapeutic effect of melatonin in combination with sorafenib on
hepatocellular carcinoma (HCC) cells. Their results showed that
melatonin, through inhibition of mechanistic target of rapamycin,
attenuates regulation of HIF‐1α, leading to the attenuation of
cytoprotective effect of hypoxia microenvironment against sorafenib
(Prieto‐Domínguez et al., 2017). Another study by this group showed
that melatonin enhances the production of ROS through depolariza-
tion of mitochondria in HCC cells. Also, it seems that upregulation of
Bax and mitophagy are involved in the cytotoxic activity of melatonin
combination with sorafenib (Prieto‐Domínguez et al., 2016). Another
study showed that activation of JNK/c‐jun pathway by melatonin is
involved in apoptosis induction by melatonin when it is combined
with sorafenib (Lin et al., 2017). Liu et al. showed that increased
autophagy is a reason for increasing the resistance of HCC cells to
sorafenib. Melatonin, through suppression of autophagy, may further
sensitize HCC cells to sorafenib (Y. Liu et al., 2017).
8 | CONCLUSION
Melatonin is a potent anticarcinogenic agent against different toxic
agents such as ionizing and nonionizing radiation, and chemotherapy
agents. It has been shown that melatonin protects normal cells against
development of malignancies at different levels. At the first level,
melatonin neutralizes free radicals directly or indirectly via enhancement
of antioxidant defense. Anti‐inflammatory effect of melatonin can prevent
development of chronic oxidative stress, a phenomenon, which is
associated with genomic instability. Moreover, melatonin is able to boost
DNA repair enzymes to prevent mutations and genomic instability. An
interesting property of melatonin is its effects on signaling pathways
involved in DNA repair, inflammation, and cell survival in both normal and
malignant cells. Stimulation of DNA repair is critical for the attenuation of
acute reactions to radiotherapy caused by massive cell death. Moreover,
inflammation—that is potently involved in both normal tissue injury and
tumor resistance—can be inhibited by melatonin. Classical antioxidants
neutralize free radicals in both normal and tumor cells which may, in
addition to protection of normal tissues, cause reduction of tumor cells
response to radiation treatment. In contrast to other antioxidants,
melatonin can modulate inflammation and redox activity that are
involved in normal tissue injury and also tumor resistance. Melatonin
enhances DNA repair in normal cells while it can promote apoptosis via
attenuation of prostaglandins in tumor cells. These properties of
melatonin make it a promising adjuvant to both radiotherapy and
chemotherapy, which can alleviate side effects on normal tissues and
reinforce therapeutic effects on the cancerous tissue.
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